With the aim of pioneering a safe,
effective gene therapy approach, St. Jude scientists have spent years developing an innovative vector for X-linked SCID.
In recent years, scientists have grown new retinal cells from stem cells and shown progress in developing
an effective gene therapy.
Although currently there are no FDA - approved gene therapy products,
an effective gene therapy will probably gain FDA approval within the next three to five years.
A review of recent progress toward developing
effective gene therapies for use in «regenerative surgery» appears in the June issue of Plastic and Reconstructive Surgery ®, the official medical journal of the American Society of Plastic Surgeons (ASPS).
The trial stemmed from a decade - long collaboration between St. Jude and University College London to discover
effective gene therapies for this blood disorder.
Not exact matches
Paul Dabrowski, CEO and co-founder of Synthego, shared with me in email that, «It's possible to imagine a day when
gene therapies are safe,
effective, easy and affordable for anyone who needs them.
Companies are also finding that using M&A to acquire R&D capabilities is an
effective way to build positions in emerging technologies such as
gene therapy and biosimilars.
The principles that have emerged thus far are these: We should seek new knowledge of our
genes (and we can say this without deciding whether the Human Genome Initiative is the wisest and most cost -
effective way to do so) We should seek
therapies for the genetic disorders that afflict many people.
The finding offers potential for developing both
gene therapy and more
effective protein replacement treatments for hemophilia A, the most common form of hemophilia.
The laboratories also collaborated to successfully prove that reversing a protein deficiency through
gene therapy is
effective in improving and stabilizing SMA in a large animal model.
«
Genes may cause tumor aggressiveness, drug resistance in African - American prostate cancer: Research found many targeted
therapies for prostate cancer may not be
effective against tumors in African - American men.»
Despite much effort, no one has managed to develop an
effective form of
gene therapy to treat the lung problems of people with cystic fibrosis.
But for a
gene therapy to be
effective, one must know the precise
gene responsible for a given individual's disorder and develop a tailored treatment.
The method, reported in the November issue of Nature Biotechnology, could lead to safe and
effective human
gene therapies for cystic fibrosis, hemophilia, and a variety of other diseases.
«Research into basic workings of immune system points to way of improving
therapies for cancer: Differences in wiring of «exhausted» and
effective T cells indicate possible
gene - editing targets.»
Researchers at Massachusetts Eye and Ear / Schepens Eye Research Institute have reconstructed an ancient virus that is highly
effective at delivering
gene therapies to the liver, muscle, and retina.
As the central nervous system is also a target of AAV vectors, Hélène Puccio and Patrick Aubourg's teams are investigating whether a similar approach using
gene therapy could be as
effective for the spinal cord and cerebellum as it is for the heart.
Because the vaccine causes the body to mount an immune response directed against a unique tumor, the
therapy is much more
effective than
gene - targeted or more general chemotherapy alone.
«Because this mutation already exists in nature and is benign, this «organic
gene therapy» approach should be
effective and safe to use to treat, and possibly cure, serious blood disorders.
Gene therapy within the next decade or so is not going to prove very
effective in eliminating solid cancers such as lung, breast, prostate, colon and so on.
According to Saura, «this study opens up new perspectives on therapeutic prevention and treatment of Alzheimer's disease, given that we have demonstrated that a
gene therapy which activates the Crtc1 protein is
effective in preventing the loss of memory in lab mice».
If confirmed, a connection between AMD and these extracellular matrix
genes may allow for predictive genetic tests and more
effective therapies for people with this type of AMD.
For very rare diseases such as WAS, multicenter clinical trials are the only
effective way of proving the safety and efficacy of
gene therapy and having it rapidly approuved and made available to all patients.
This approach for
gene therapy to treat fatty liver disease, for example, might prove both safer and more
effective than reengineering cells in the liver itself.
Professor Thrasher says: «This is a very powerful example of how
gene therapy can offer highly
effective treatment for patients with complex and serious genetic disease.
While
effective, the downside to these approaches to vision rescue is that each disease requires its own form of
gene therapy to correct the particular genetic mutation involved, a time consuming and complex process.
Hence, scientists have begun studying BRCA - targeted
gene therapy as an
effective treatment for breast cancer.
To support work that can significantly contribute to a better understanding of the
gene / protein leucine - rich repeat kinase 2 (LRRK2), its relevance to Parkinson's disease (PD) and
effective ways to translate LRRK2 research into
therapies for patients.
«These results are an exciting early indication that this
gene therapy is well tolerated and effective in infants as young as 2 months old with this devastating inherited immune disorder,» said Ewelina Mamcarz, M.D., an assistant member of the St. Jude Department of Bone Marrow Transplantation and Cellular T
therapy is well tolerated and
effective in infants as young as 2 months old with this devastating inherited immune disorder,» said Ewelina Mamcarz, M.D., an assistant member of the St. Jude Department of Bone Marrow Transplantation and Cellular
TherapyTherapy.
In the second half of the study, we will test whether our
gene therapy vector is
effective at halting the progression of an optic neuropathy in rodents.
«These early results in infants reinforce hope that
gene therapy will prove to be safe and
effective at restoring immune function early in life,» said Brian Sorrentino, M.D., a member of the St. Jude Department of Hematology, who leads this study with Mamcarz.
The only plausible methods of repairing stochastic nuclear DNA damage look to be the aforementioned advanced molecular nanotechnology, something that lies some decades in the future, or major advances in
gene therapy, to the point at which it could be cost -
effective and safe to scan and conditionally alter the majority of
genes in the majority of cells all at once.
Ewelina Mamcarz, M.D., presents research at the annual ASH conference that indicates that the St. Jude XSCID
gene therapy has been well tolerated and
effective for infants as young as 2 months old.
Since the initial Michigan trial, the liposomal transport system — developed by researchers at Vical, a San Diego - based biopharmaceutical company interested in
gene therapy — has been altered in ways that are expected to make it safer, more
effective and easier to administer.
Preliminary findings indicate
gene therapy pioneered at St. Jude Children's Research Hospital is safe and
effective for babies with a devastating inherited disorder that leaves them with little or no immune protection
The co-delivery of small molecular drugs with nucleic acids can improve
gene transfection efficiency, reduce side - effects of these drugs, and achieve the synergistic effect of drug and
gene therapy for the more
effective treatment of cancer.
Gene therapy to replace the protein missing in Pompe disease can be
effective if the patient's immune system does not...
National Cancer Institute and ECOG - ACRIN announce the July 2015 opening of the NCI - MATCH / EAY131 trial, a multi-arm phase II precision medicine study that seeks to determine whether targeted
therapies for people whose tumors have specific
gene mutations will be
effective regardless of cancer type.
The significance of this trial indicates that
gene therapy may be
effective in halting cancer progression.
The mission of ACGT is to support the extraordinary potential offered by cell and
gene - based
therapies to accelerate
effective and safe treatment of all types of cancer.